Article detail · 2013
Application of soft sets to diagnose the prostate cancer risk
- Year
- 2013
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue Journal of Inequalities and Applications
- Catalog match (ISSN) Journal of Inequalities and Applications
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
OpenAlex · English
Abstract In recent years the artificial intelligence has been developed rapidly since it can be applied easily to several areas like medical diagnosis, engineering and economics, among others. In this study we have devised a soft expert system (SES) as a prediction system for prostate cancer by using the prostate specific antigen (PSA), prostate volume (PV) and age factors of patients based on fuzzy sets and soft sets and have calculated the patients’ prostate cancer risk. Our data set has been provided by the Department of Urology, Meram Medical Faculty in Necmettin Erbakan University, Konya, Turkey.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
123 citations
OpenAlex cited_by_count (cache / database)
28 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- Interval-valued neutrosophic soft sets and its decision making 2017
- Network-Induced Soft Sets and Stock Market Applications 2022
- Network-Induced Soft Sets and Stock Market Applications 2022
- An application of multicriteria group decision making by soft covering based rough sets 2015
- An Application of Soft Set and Fuzzy Soft Set Theories to Stock Management 2017
- Analysis of semigroups with soft intersection ideals 2022
- Optimization of Lactic Acid Bacteria Viability Using Fuzzy Soft Set Modelling 2018
- Hayat ve hayat dışı sigortalar için karar verme problemi 2018
- Decision Making Problem for Life and Non – Life Insurances 2018
- Consistency measurement using the artificial neural network of the results obtained with fuzzy topsis method for the diagnosis of prostate cancer 2021